Fig. 7: Ferroptosis inhibitor DFO restores anti-tumor immunity in Depdc5^tko mice.

a Depdc5^ncl and Depdc5^tko mice were injected subcutaneously with 5 × 10⁵ MC38 tumor cells at day 0. Both Depdc5^ncl and Depdc5^tko mice were divided into two groups: the first group received I.P. injection with 200 μg/kg/day DFO, while the second group received I.P. injection vehicle only, beginning day 1 after tumor inoculation. Tumor volumes were then measured at the indicated time points (n = 5). b Photograph of MC38 tumors from Depdc5^ncl and Depdc5^tko mice treated with vehicle only or DFO prior to sacrifice on day 23 after tumor inoculation (n = 5). c Summary bar graph showing tumor weight in Depdc5^ncl and Depdc5^tko mice treated with vehicle only or DFO prior to sacrifice on day 23 after tumor inoculation. d Flow cytometry analysis of tumor-infiltrating CD4⁺ and CD8⁺ T cell percentages within the CD45⁺ pool of MC38 tumors from Depdc5^ncl and Depdc5^tko mice treated with vehicle or DFO. At day 23 after tumor inoculation, single-cell suspensions of each tumor were isolated from individual mice, then stained with a fixable viability dye and antibodies against CD45 and CD8 prior to analysis by flow cytometry. e Summary bar graph showing tumor-infiltrating CD8⁺ T cell percentage within the CD45⁺ pool of tumor tissue as in d. f Mice were inoculated with KLN205 cells, treated with vehicle or RSL3 from day 5 to day 7, and received anti-PD1 or isotype control antibodies on day 10 and day 14. g Comparison of KLN205 tumor growth curve in Vehicle-Isotype, Vehicle-anti-PD1, and RSL3-anti-PD1 conditions treated as f. Error bars indicate means ± SEM (NS, not significant, *P < 0.05, **P < 0.01 by unpaired Student’s t-test).